SecBot SecBot

IMUX

IMMUNIC, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001280776 Biotech & Drug Discovery
$7.15 −0.26 (−3.51%)
Oct 26 4:00 PM ET · prev $7.41
Market cap
$98.5M
Micro cap
Consensus
Buy
94% Buy or better · 18 analysts
Median target
$30.00
+320% · range $22.00–85.00
Next earnings
Nov 11
in 16 days · EPS est. −$0.95
1 year
−14.4%
from $8.35 · Oct 27
30 days
−24.8%
from $9.51
52-week range
$5.10–16.90
−58% from high · low Dec 30
Avg volume 20D
426.6K
shares / day
Short interest
2.08M
≈15.2% of shares · +15.7%
Days to cover
4.6
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
2
Q2 2026 13F · 0 exits
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Immunic reported Q2 2026 net loss of $34.1M ($0.80/share), roughly matching the Street consensus of -$1.24…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 2 added (2 new), 1 trimmed or exited. Largest new: Aberdeen Group $12.7M, Millennium Management $11.4M.

  • AnalystsBULLISH

    17 of 18 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$1.193 → −$0.950 over 90 days. 7 up, 3 down in 30 days.

  • Short sellersBUILDING

    Short interest +15.7% to 2.08M shares. 4.6 days to cover, ≈15.2% of shares.

  • TrendDOWNTREND

    35% below its 50-day average.

Who's buying

13F· Q2 2026
2
new positions
0
exits
$24.1M
in new stakes
FundMoveSharesValue
Aberdeen Group plcNEW824,393$12.7M
MILLENNIUM MANAGEMENT LLCNEW740,347$11.4M
MARSHALL WACE, LLPNEAR_EXIT104,816$1.6M
MORGAN STANLEYADD3,288,540$3.7M
GEODE CAPITAL MANAGEMENT, LLCADD1,525,769$1.7M
BlackRock, Inc.ADD964,230$1.1M
JANE STREET GROUP, LLCDOUBLED659,153$731.7K
STATE STREET CORPADD565,645$627.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 94% rate it Buy or better
Strong Buy9Buy8Hold1Sell0Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +320%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 23, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
Sep 10, 2026Wedbush
REITERATE
REITERATEOutperform
Sep 10, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 17, 2026Wedbush
INITIATE
INITIATEOutperform
May 22, 2026B. Riley Securities
MAINTAIN
MAINTAINBuy
Apr 30, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 16, 2026
BVF PARTNERS L P/IL
Director
AWARD25,370 sh
Sep 16, 2026
Nagel Robert Thorvald
Director
AWARD25,370 sh
Aug 6, 2026
Ridloff Elena
Director
AWARD50,740 sh
Jul 5, 2026
PHILLIPS BARCLAY A
Director
AWARD25,370 sh
Jul 5, 2026
Congleton Jon
Director
AWARD25,370 sh
Jul 5, 2026
Neermann Joerg
Director
AWARD25,370 sh
Jul 5, 2026
Skerjanec Simona
Director
AWARD25,370 sh
Jul 5, 2026
Rudick Richard Alan
Director
AWARD25,370 sh

Earnings setup

Estimates
Nov 11
reports in 16 days
−$0.95
EPS estimate, this quarter
+20%
estimate change, 90 days
7↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.95-$2.58–-$0.67+1.2%$0.00
Next Q-$0.82-$1.26–-$0.57-0.0%$0.00
Current FY-$3.56-$5.72–-$3.09+0.1%$0.00
Next FY-$2.36-$4.68–-$0.70+2.7%$0.00

Short side

FINRA· Sep 30, 2026
2,075,709
shares short
+15.7%
vs prior settlement
4.6
days to cover
≈15.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 Other
Immunic Appoints Jaa Roberson as Chief People Officer
– Appointment Supports Immunic's Strategy to Build a Leading Multiple Sclerosis Organization Ahead o
Sep 16, 2026 Insider
BVF PARTNERS L P/IL was granted 25,370 shares
Director
Sep 16, 2026 Insider
Nagel Robert Thorvald was granted 25,370 shares
Director
Sep 9, 2026 SEC
Immunic, Inc. filed an 8-K announcing a Relapsing Multiple Sclerosis (RMS) Research and Development Day webinar held…
8-K — Impact 3/10
Aug 11, 2026 SEC
Immunic reported Q2 2026 net loss of $34.1M ($0.80/share), roughly matching the Street consensus of -$1.24 (narrower…
8-K — Impact 5/10
Aug 6, 2026 Insider
Ridloff Elena was granted 50,740 shares
Director
Jul 14, 2026 SEC
Immunic filed an 8-K disclosing an updated corporate investor presentation on its website. The filing is a routine…
8-K — Impact 2/10
Jun 30, 2026 Inst.
Aberdeen Group plc — NEW
824,393 shares ($12.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
IMUX Q3 2026 Earnings Before Market Open — 2026-11-11
Recent
Oct 19, 2026
Press release
Immunic Appoints Jaa Roberson as Chief People Officer
– Appointment Supports Immunic's Strategy to Build a Leading Multiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated…
Sep 15, 2026
Short interest
Short Interest: IMUX up 20% to 1.8M shares
Settlement 2026-09-15 | Days to cover: 5.04 | ≈13.15% of shares outstanding (est.)
Sep 2, 2026
Press release
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral…
Aug 5, 2026
Earnings date
IMUX Q2 2026 Earnings Before Market Open — 2026-08-05
Jul 31, 2026
Short interest
Short Interest: IMUX up 1% to 1.4M shares
Settlement 2026-07-31 | Days to cover: 10.13 | ≈10.52% of shares outstanding (est.)

SecBot reports

11 filings · 1 bullish · 1 bearish · 9 neutral
All IMUX filing & press-release reports (11)